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Most patients with adenocarcinoma of the pancreas present locally
advanced or metastatic disease at the time of diagnosis. With only
about 1% of patients still alive 5 years from the time of diagnosis,
these patients have a very poor prognosis. Gemcitabine (2¢,2¢-
difluorodeoxycytidine), a nucleoside analogue with a mild toxicity
profile (Aapro et al, 1998), has been shown to improve both clin-
ical benefit and survival in patients with advanced pancreatic
cancer compared to treatment with 5-fluorouracil, although overall
survival was poor with a median survival of less than 6 months
(Burris et al, 1997). To identify any subgroups of patients in which
chemotherapy with gemcitabine improves survival, prognostic
parameters during the first cycles of chemotherapy would be
helpful. Unfortunately, assessment of tumour diameters by
imaging techniques to monitor response to chemotherapy are often
inaccurate (Rothenberg et al, 1996b).
Serum carbohydrate antigen 19–9 (CA 19–9), the sialylated
Lewisa blood group antigen defined by the monoclonal antibody
1116 NS 19–9 (Koprowski et al, 1979), has been proved as the
most sensitive and specific serum marker for pancreatic cancer
(Pleskow et al, 1989; Rollhauser and Steinberg, 1998). The prog-
nostic value of CA 19–9 for patients with pancreatic cancer treated
with resection or radiotherapy is well established (Glenn et al,
1988; Katz et al, 1998; Rollhauser and Steinberg, 1998), but only
few data regarding the prognostic value of CA 19–9 during
chemotherapy with gemcitabine have been published so far.
The aim of the study was therefore to assess the prognostic
value of the tumour marker CA 19–9 in patients with advanced or
metastatic pancreatic cancer treated with gemcitabine.
PATIENTS AND METHODS
Patients
Adult patients were included in this prospective study if they had
metastatic or locally advanced, inoperable pancreatic cancer, a
baseline Karnofsky performance status ³ 60%, and histological
diagnosis of ductal adenocarcinoma, which was obtained either
percutaneously or during operation. Patients who had received
previous chemotherapy or radiotherapy were excluded from the
analysis. All patients received chemotherapy with gemcitabine as
a single agent therapy as previously described (Rothenberg et al,
1996a; Burris et al, 1997). During the first cycle patients received
gemcitabine in a dose of 1000 mg m–2 once weekly for 7 weeks
followed by 1 week of rest. Thereafter, gemcitabine was given
once weekly for 3 weeks followed by 1 week of rest until progres-
sion of the disease. Progression was defined either by an increase
of >25% of the longest perpendicular diameters of a mass lesion,
the occurrence of a new lesion or malignant ascites, or a deteriora-
tion of performance status with inability of the patient to attend
follow-up visits.
Measurements
Serum samples for determination of the tumour marker CA 19–9
were obtained from every patient at baseline, after the first cycle (8
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tion during chemotherapy, exchange of the stent was performed
before serum samples were obtained. The CA 19–9 concentration
was measured by a commercially available enzyme immunoassay
(Enzymun-Test CA 19–9, Roche Diagnostics, Germany). The cut-
off value given by the manufacturer was 22 U l–1. The coefficient
of variation in our laboratory was 7% (n = 27). Taking the coeffi-
cient of variation into account, a fall of CA 19–9 during
chemotherapy was defined as a decrease > 20% after the first cycle
(8 weeks) of chemotherapy.
Statistical analysis
Unadjusted median survival curves were constructed according to
Kaplan and Meier (Kaplan and Meier, 1958). Differences in
survival were calculated with the log-rank test and correlations
with Spearman’s rank correlation test. The proportional hazard
multivariate model (Cox, 1972) was used to evaluate the relation-
ship of differences of survival to patient and disease characteris-
tics, which might influence the prognosis. Data showing
significance or a trend for significance (P < 0.20) by univariate
analysis were included in the multivariate model. A two-sided P-
value < 0.05 was considered as statistically significant.
RESULTS
The patient characteristics are listed in Table 1. Forty-three
patients were consecutively included. The median age was 61
years (range 39–76 years), 20 patients were male and 23 female.
Twenty-eight patients had evidence of metastatic disease and 15 of
locally advanced disease. Prior to chemotherapy, eight patients
with obstructive jaundice underwent endoscopic biliary prosthesis.
Twelve patients had undergone palliative operation and seven
patients had recurrent metastatic disease after previous Whipple’s
pancreatoduodenectomy. Most patients had moderately or poorly
differentiated ductal adenocarcinoma. Seven patients (16%) were
excluded from further analysis because no serial measurements
could be performed. Five of these patients had normal CA 19–9
values at baseline and two were lost to follow-up. The 36
remaining patients were treated with a median cumulative dose of
15 g m–2 (range 3–55 g m–2). In 97% of the gemcitabine adminis-
trations doses were given on schedule. During 8 cycles a dose
reduction was necessary due to haematological toxicity grade 3.
The median baseline CA 19–9 concentration of the remaining 36
patients was 1515 U l–1 (range 34–43 553 U l–1).
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Table 1 Baseline patient characteristics
Patient characteristics
Age – years (range) 61 (39–76)
Males/Females – n 20/23
Median baseline CA 19–9 – U l–1 (range)a 1515 (34–43553)
Tumour stage (UICC 1997) – n
III/IVa 15
IVb 28
Tumour grading – n
I4
II 26
III 12
IV 1
Previous operation – n
Whipple’s pancreatoduodenectomy 7
Cholangiojejunostomy 6
Gastroenterostomy 2
Cholangiojejunostomy and gastroenterostomy 4
Biliary prosthesis – n 8
a Patients with serial CA 19–9 measurements (n = 36). Normal value of CA
19–9: < 22 U l–1.
Figure 1 Survival time in relation to the log alteration of CA 19–9 after 8
weeks of chemotherapy with gemcitabine (r = – 0.55, P = 0.001)
Figure 2 Survival curves using the Kaplan–Meier method comparing the
survival of patient with a CA 19–9 decrease > 20% ( ) and ≤ 20% or a
primary rise ( ) during the first 8 weeks of chemotherapy with
gemcitabine. Patients with a CA 19–9 response > 20% had a significantly
better median survival than patients with no response (268 vs 110 days; P <
0.001)
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0A significant correlation between the percental alteration of CA
19–9 concentration and survival was found (r = – 0.55; P = 0.001;
Figure 1). Twenty-five (69%) of the 36 patients had a response of
CA 19–9 to treatment with gemcitabine and 11 (31%) a progres-
sive rise (n = 9) or a decrease of ≤20% (n = 2) of the CA 19–9
concentration. The median overall survival of the 36 patients with
increased baseline CA 19–9 concentrations was 211 days (95%
confidence interval (CI) 155–267 days). However, patients
responding with CA 19–9 decrease > 20% had a median survival
of 268 days (95% CI 123–413 days), which was significantly
longer than the median survival of the patients who did not
respond (110 days; 95% CI 83–137 days; P < 0.001; Figure 2). The
median survival of patients with normal CA 19–9 concentrations
at baseline was 168 days (95% CI 54–282). Similar results were
obtained regarding time to progression. Patients responding with
CA 19–9 > 20% had a significantly longer median time to progres-
sion (173 days; 95% CI 136–210 days) than patients who did not
respond (75 days; 95% CI 41–109 days; P < 0.001).
After 8 weeks of chemotherapy, objective partial response was
achieved in four patients (11%). All of them had a CA 19–9
decrease > 20%. Nineteen of the 25 patients with stable disease
and two of seven with progressive disease after 8 weeks of treat-
ment had decreasing CA 19–9 concentrations > 20%. Eighteen of
the 25 patients responding with the tumour marker CA 19–9 
> 20% experienced a recurrent increase. The median survival time
from the beginning of recurrent rise to death was 96 days (95% CI
65–127 days).
Age and gender did not show significant or a trend for signifi-
cant differences regarding survival by univariate analysis 
(P > 0.20). The alteration of CA 19–9 concentration, tumour stage
and grading, previous operation, biliary stenting and the CA 19–9
concentration at baseline were included in the multivariate
analysis. The Cox regression analysis showed the fall of CA 19–9
> 20% as the strongest independent factor for survival time.
Tumour grading and the baseline CA 19–9 concentration, but
neither surgical bypasses, biliary stenting, nor tumour stage had a
significant influence on survival (Table 2).
DISCUSSION
The prognosis of patients with locally advanced or metastatic
pancreatic cancer is poor. All chemotherapeutic regimens used in
the last decades failed to improve survival substantially (Ahlgren,
1996; Schnall and Macdonald, 1996). Recently, chemotherapy
with gemcitabine has been shown for the first time to improve
significantly both survival and quality of life in patients with
advanced pancreatic cancer, although overall survival was poor
and the majority of patients treated did not respond (Rothenberg et
al, 1996a; Burris et al, 1997). The response of most solid tumours
to chemotherapy is controlled by imaging techniques. A major
problem of measuring tumour response during chemotherapy of
pancreatic cancer is that computerized tomography, ultrasound,
and other imaging techniques often fail to differentiate normal
pancreas, local inflammation, and fibrosis from malignant tissue
and therefore may be inaccurate in the assessment of the response
(Rothenberg et al, 1996b). Consequently, the endpoints to assess
tumour response were expanded by clinical parameters and quality
of life, which has been proposed to be more appropriate than
assessment of tumour diameters (Rothenberg et al, 1996b; Burris
et al, 1997). However, these parameters are difficult to obtain and
the results of the present study indicate that serial measurements of
CA 19–9 concentrations during therapy with gemcitabine are
useful to assess prognosis.
In accordance to previous studies, the overall survival in our
study was poor with none of the patients surviving longer than 28
months (Rothenberg et al, 1996b; Burris et al, 1997). However, a
fall of CA 19–9 > 20% after 8 weeks of chemotherapy was found
to separate patients into groups with significantly different
survival times. Moreover, not only the primary, but also a recurrent
rise of CA 19–9 after an initial response was associated with a
short median survival time of the patients. The presence of
metastatic disease, high baseline tumour marker concentrations,
and a poor performance status has been described as unfavourable
prognostic factors (Lundin et al, 1994; Ishii et al, 1996). In
contrast, in the multivariate analysis of our study, the alteration of
CA 19–9 was the strongest independent prognostic factor. Since
the median survival time of patients with a decrease of CA 19–9 ≤
20% or a rise during the first cycles of chemotherapy or with a
recurrent rise after initial response is very short, the measurement
of CA 19–9 after 8 weeks of chemotherapy may together with
other clinical parameters help to decide, whether further
chemotherapy should be stopped.
Two of seven patients had falling CA 19–9 concentrations after
8 weeks of treatment despite disease progression. Similar results
were obtained in a phase II trial treating patients with locally
advanced or metastatic pancreatic cancer with gemcitabine, in
which serial measurements were performed in 14 patients with
evaluable disease. All patients with radiologically assessed partial
response (n = 2) or stable disease (n = 5), but also four of seven
patients with progressive disease exhibited a decrease of CA 19–9
during the course of chemotherapy (Carmichael et al, 1996). These
inconsistent results remain difficult to interpret, but may be related
to the inaccuracies in the assessment of tumour size.
The prognostic value of CA 19–9 has already been established
in patients undergoing radiation or resection of pancreatic carci-
noma. A better survival was found in patients responding with a
falling CA 19–9 following radiotherapy (Katz et al, 1998;
Okusaka et al, 1998). Increased CA 19–9 concentrations after
resection of pancreatic cancer has been reported to be associated
with poor survival compared with patients whose CA 19–9 had
been normalized (Glenn et al, 1988; Tian et al, 1992; Safi et al,
1998). High preoperative concentrations of CA 19–9 correlate 
also with poor survival (Lundin et al, 1994; Safi et al, 1998). 
A decrease of > 15% of CA 19–9 concentrations during
chemotherapy with 5-fluorouracil, epirubicin, and cisplatin has
been shown to correlate with a better survival than a primary rise
or a plateau of the CA 19–9 concentration. Patients with a decrease
of > 15% of CA 19–9 had no progression of their disease as
assessed by computerized tomography (Gogas et al, 1998). In
contrast to our results, only 13 of 36 patients (36%) responded
CA 19–9 in pancreatic cancer 1015
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Table 2 Possible prognostic factors identified by the Cox proportional
hazards model
Variable Relative risk P-value
(95% confidence interval)
CA 19–9 response (> 20% vs. ≤ 20%) 12.7 (4.3–38.1) < 0.001
Tumour grading (I/II vs. III/IV) 3.4 (1.4–8.3) 0.008
Tumour stage (III/IVa vs. IVb) 1.7 (0.7–4.1) 0.25
Baseline CA 19–9 concentration (quartiles) 1.4 (1.0–2.0) 0.04
Prior palliative operation/Biliary stenting 1.2 (0.8–1.9) 0.35with a fall of CA 19–9 to the chemotherapy regimen. However,
these results confirm that CA 19–9 helps to assess prognosis
during chemotherapy of pancreatic cancer.
In conclusion, in patients with advanced or metastatic pancre-
atic cancer and increased baseline CA 19–9 concentrations,
measurements of CA 19–9 should be performed after 8 weeks of
treatment to assess prognosis together with other clinical parame-
ters. In patients with an increase of CA 19–9 or with a decrease 
≤ 20%, prognosis is extremely poor and with the exception of
cases with significant improvement of performance status, further
chemotherapy with gemcitabine seems of questionable value.
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